Papadopoulos will report directly to Emergex's CEO Professor Thomas Rademacher.
In his new role Papadopoulos will use his extensive medical, regulatory and clinical development expertise to provide leadership and direction on the development of Emergex's growing pipeline of vaccines.
Papadopoulos joins Emergex from Sanofi, the global pharmaceutical company, where he was most recently Associate vice president, senior director and Clinical Franchise Leader of Global Clinical Sciences since 2015. During his time at Sanofi Dr. Papadopoulos played a critical role in the development of Dengvaxia, the first vaccine approved for Dengue fever.
Prior to joining Sanofi, Dr. Papadopoulos worked at Novartis as Medical Affairs director and Senior Global Clinical Research Physician as well as Lead Head of CLS and Senior director of Clinical Development. During his time at Novartis, he contributed to the successful development and approval of the breakthrough Bexsero Meningitis B vaccine.
Papadopoulos originally trained as a general practitioner in Greece and specialized as a clinical bio-pathology consultant.
Emergex Vaccines Holding, a UK-based biotechnology company headquartered in Oxford, is developing a new approach to vaccine development in order to address some of the world's most immediate health threats including Flaviviruses, such as Dengue Fever and Zika as well as Filoviruses, such as Ebola and Marburg viruses, and seasonal and pandemic influenza.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma